Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.32 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CA3 | P07451 | 2/20 | 0.31 |
| ▸ | CA5A | P35218 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | CA4 | P22748 | 1/20 | 0.31 |
| ▸ | CA6 | P23280 | 1/20 | 0.31 |
| ▸ | CA7 | P43166 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4469009 | 0.98 | KDM4C (0.41) | KDM4CCA2ARALDH1A1POLB | |
| SCHEMBL14040406 | 0.79 | KDM4C (0.45) | KDM4CARALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL4469005 | 0.78 | CA2 (0.40) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL6462033 | 0.76 | CA2 (0.39) | CA2ALDH1A1POLBSMN1; SMN2TSHR | |
| SCHEMBL6462028 | 0.76 | CA2 (0.39) | CA2ALDH1A1POLBSMN1; SMN2TSHR | |
| SCHEMBL2757992 | 0.76 | CA2 (0.48) | CA2ALDH1A1POLBSMN1; SMN2MEN1 | |
| SCHEMBL14384504 | 0.75 | KDM4C (0.42) | KDM4CARALDH1A1TSHRMAPT | |
| SCHEMBL22855366 | 0.75 | KDM4C (0.42) | KDM4CARALDH1A1TSHRMAPT | |
| SCHEMBL11739867 | 0.75 | ALDH1A1 (0.43) | KDM4CARALDH1A1TSHRMEN1 | |
| SCHEMBL30066024 | 0.75 | KDM4C (0.42) | KDM4CARALDH1A1TSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-11-20 | — | — | US | disclosed |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-02 | — | — | US | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4509517-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-02-19 | — | — | EP | disclosed |
| CN-114630835-B | Process for the preparation of peptide compounds comprising sterically bulky amino acids | 中外制药株式会社 | 2025-02-11 | — | — | CN | disclosed |
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-20230391818-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-12-07 | — | — | US | disclosed |
| WO-2023214577-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | 中外製薬株式会社 | 2023-11-09 | — | — | WO | disclosed |
| EP-0743857-A4 | METHOD OF MAKING POLYMERS HAVING SPECIFIC PROPERTIES | ARQULE INC (US) | 1998-07-15 | — | — | EP | disclosed |
| EP-0737232-A4 | MODULAR DESIGN AND SYNTHESIS OF AMINIMIDE CONTAINING MOLECULES | ARQULE INC (US) | 1997-11-26 | — | — | EP | disclosed |
| EP-0743857-A1 | METHOD OF MAKING POLYMERS HAVING SPECIFIC PROPERTIES | ARQULE, INC. (US) | 1996-11-27 | — | — | EP | disclosed |
| EP-0737232-A1 | MODULAR DESIGN AND SYNTHESIS OF AMINIMIDE CONTAINING MOLECULES | ARQULE, INC. (US) | 1996-10-16 | — | — | EP | disclosed |
| US-5538988-A | CARDIOVASCULAR DISORDERS AND DOPAMINE HYDROLASE ENZYME INHIBITORS | SYNTEX (U.S.A.) INC. | 1996-07-23 | — | — | US | disclosed |
| WO-1995018627-A1 | METHOD OF MAKING POLYMERS HAVING SPECIFIC PROPERTIES | ARQULE, INC. (US) | 1995-07-13 | — | — | WO | disclosed |
| WO-1995018186-A1 | MODULAR DESIGN AND SYNTHESIS OF AMINIMIDE CONTAINING MOLECULES | ARQULE PARTNERS, L.P. (US) | 1995-07-06 | — | — | WO | disclosed |
| EP-0015773-B1 | N-(6-((ACYLAMINOACYLAMINO OR AMINOACYLAMINO)PHENYL) 1,2-DIHYDRO-2-OXONICOTINYL)PENICILLIN COMPOUNDS, PROCESSES FOR THEIR PRODUCTION AND COMPOSITIONS CONTAINING THEM | WARNER-LAMBERT COMPANY (US) | 1983-07-20 | — | — | EP | disclosed |
| US-4278681-A | N-/6-//ACYLAMINOACYLAMINO OR AMINOACYLAMINO/PHENYL/-1,2-DIHYDRO-2-OXONICOTINYL/PENICILLINS | WARNER-LAMBERT CO. (US) | 1981-07-14 | — | — | US | disclosed |
| EP-0015773-A2 | N-(6-((acylaminoacylamino or aminoacylamino)phenyl) 1,2-dihydro-2-oxonicotinyl)penicillin compounds, processes for their production and compositions containing them | WARNER-LAMBERT COMPANY (US) | 1980-09-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240400617-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | KDM4C 4445/4885CA2 1953/4885AR 4219/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | KDM4C 4755/4885CA2 985/4885AR 3023/4885 |
| US-20230391818-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, DNPEP, NPPA | KDM4C 2977/4885CA2 2955/4885AR 3598/4885 |
| US-12404299-B2 | Method for producing peptide compound comprising highly sterically hindered amino acid | DNPEP, VIP, NPEPPS | KDM4C 4665/4885CA2 3659/4885AR 1681/4885 |
| US-20250353875-A1 | PEPTIDE SYNTHESIS METHOD FOR SUPPRESSING DEFECT CAUSED BY DIKETOPIPERAZINE FORMATION | VIP, NPPA, DNPEP | KDM4C 2693/4885CA2 2848/4885AR 3660/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | KDM4C 4445/4885CA2 1953/4885AR 4219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.